Navigation Links
AlphaVax Announces New Vice President of Regulatory, Quality and Clinical Operations
Date:2/16/2009

RESEARCH TRIANGLE PARK, N.C., Feb. 16 /PRNewswire/ -- AlphaVax announced today that it has hired Lynn Baird, PhD, as Vice President of Regulatory, Quality and Clinical Operations. In this capacity Lynn will provide leadership and strategic direction in the areas of regulatory and quality affairs and in clinical operations.

"Lynn's experience in directing successful clinical trials, developing regulatory strategy and gaining regulatory approval for clinical trials will complement our existing leadership team. We will look to Lynn to manage the regulatory affairs for in-house programs at AlphaVax as they move through clinical development, as well as coordinate and support regulatory activities of corporate partners involved with our alphavirus vector platform," said Andrew Graham, Vice President of Development at AlphaVax.

Most recently, Lynn was Sr. Vice President, Regulatory, Quality and Clinical Operations with CombinatoRx, Inc. in Cambridge, MA. Previous to that appointment, she held executive management positions for regulatory affairs and quality at Dyax, Curis and CytoTherapeutics. Lynn earned her Ph.D. in Microbiology and Immunology from Virginia Commonwealth University in Richmond, Virginia.

"We are truly delighted to attract someone of Lynn's caliber, capability and expertise. There is no doubt that she will play a significant role in our future growth and success as we advance multiple vaccine products through clinical development," said Jonathan Gelles, Chairman of AlphaVax's Board of Directors.

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a proprietary alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. The company's business strategy is to maximize the potential of this platform through a mixture of in-house and partnered programs. The AlphaVax technology is currently being used to advance vaccines for influenza, cytomegalovirus, herpes simplex virus, respiratory syncytial virus, a range of cancers, HIV and a number of biodefense targets. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP-compliant manufacturing facility is located in Lenoir, NC.


'/>"/>
SOURCE AlphaVax
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardinal Health Announces New Name for Spinoff Company
2. ATS Medical Announces Fourth Quarter 2008 Earnings Release Date and Conference Call
3. URAC Announces Agenda for 2009 Best Practices in Health Care Consumer Empowerment and Protection Conference
4. Hill-Rom Announces Second Quarter 2009 Dividend
5. Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million;
6. Stemedica Announces the Appointment of Riccardo Nisato, MBA, PhD as Director of Manufacturing and Clinical Business Development for Stemedica International
7. QLT announces that it is named as a defendant in an action
8. Biotel Announces Profitable Second Quarter Ended December 31, 2008
9. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
10. Investor Group Commends Jim Merselis for Joining Trinity Biotechs Board of Directors & Announces Conference Call Invitation
11. Cogdell Spencer Announces Dorr as President of the Southeast Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... celebrate the profession and recognize the positive impact veterinarians have on animal health ... and the World Organization for Animal Health (OIE) choose a theme each year ...
(Date:4/28/2017)... NC (PRWEB) , ... April 28, 2017 , ... ... announce its new partnership with the Home Care Association of America (HCAOA). This ... and Private Duty Accreditation services, as well as discounts on Accreditation University (AU) ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Beginning in ... of their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure ... changing the formula in the following ways:, , Removal of ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark is ... with diabetes. The GlycoMark test provides a clinically proven one- to two-week measure ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology: